Letko, Brosseau & Associates’s Heron Therapeutics HRTX Stock Holding History

Letko, Brosseau & Associates’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-57,200	Closed	-$241K	–	99
2022 Q3	$241K	Hold	57,200	–	–	﹤0.01%	92
2022 Q2	$160K	Hold	57,200	–	–	﹤0.01%	94
2022 Q1	$327K	Hold	57,200	–	–	﹤0.01%	94
2021 Q4	$522K	Hold	57,200	–	–	0.01%	93
2021 Q3	$611K	Hold	57,200	–	–	0.01%	92
2021 Q2	$888K	Hold	57,200	–	–	0.01%	91
2021 Q1	$927K	Hold	57,200	–	–	0.01%	88
2020 Q4	$1.21M	Hold	57,200	–	–	0.02%	88
2020 Q3	$848K	Buy	57,200 +12,200	+27%	+$190K	0.01%	85
2020 Q2	$662K	Buy	+45,000	New	+$739K	0.01%	89

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Letko, Brosseau & Associates's HRTX Position: Q4 2022 in Review

Letko, Brosseau & Associates sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 57,200 shares — an estimated $241K sold.

Letko, Brosseau & Associates first reported a position in HRTX in Q2 2020 and held it in 10 quarters. The position peaked at $1.21M in Q4 2020. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

Letko, Brosseau & Associates reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
Letko, Brosseau & Associates sold 57,200 Heron Therapeutics shares in Q4 2022, an estimated $241K.
Letko, Brosseau & Associates first reported a position in Heron Therapeutics in Q2 2020 and held it in 10 quarters.
Letko, Brosseau & Associates's Heron Therapeutics position peaked at $1.21M in Q4 2020.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Letko, Brosseau & Associates's 13F filing for Q4 2022, filed 10 Feb 2023.